Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Brea
Go back to Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Brea| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 57.13 +0.23 (0.40%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $56.90 | 52 Week High | $77.12 | |||
| Open | $57.45 | 52 Week Low | $49.03 | |||
| Day High | $57.60 | P/E | 37.10 | |||
| Day Low | $56.77 | EPS | $1.54 | |||
| Volume | 7,839,148 | |||||
